Showing results (451-460 of 484) with videos related to
Sort By:
Pageof 49
Journal for Immunotherapy of Cancer|July 18, 2018
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)Julie R Brahmer, Ramaswamy Govindan, Robert A Anders, et al.Nature Communications|June 11, 2016
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patientsJacob J Chabon, Andrew D Simmons, Alexander F Lovejoy, et al.Proceedings of the National Academy of Sciences of the United States of America|December 14, 2016
Molecular profiling of single circulating tumor cells from lung cancer patientsSeung-Min Park, Dawson J Wong, Chin Chun Ooi, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective StudySarah Waliany, Shambo Guha Roy, Federica Pecci, et al.Nature Communications|February 7, 2026
Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategiesTadashi Manabe, Hannah C Bergo, Qingtian Li, et al.Cancer Discovery|May 3, 2015
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR InhibitorZofia Piotrowska, Matthew J Niederst, Chris A Karlovich, et al.Research Square|November 24, 2025
Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination StrategiesTadashi Manabe, Hannah C Bergo, Qingtian Li, et al.JCO Precision Oncology|April 9, 2026
Evaluating Tumor Burden as a Predictive Biomarker for Epidermal Growth Factor Receptor Targeted Kinase Inhibitor Therapy in Advanced Non-Small Cell Lung CancerRika Terashima, Judy Fan, Fatma Gunturkun, et al.Cancer|October 5, 2023
The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG-ACRIN Cancer Research Group trialsAngela Wangari Walter, Ju-Whei Lee, Joanna M Streck, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 6, 2023
Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical TrialsJoanna M Streck, Ju-Whei Lee, Angela Wangari Walter, et al.Pageof 49